Mainz Biomed NV
MYNZ
Company Profile
Business description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Contact
Robert Koch Strasse 5
Sirius Gutenberg Park
MainzRP55129
DEUT: +49 61315542860
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
71
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,594.40 | 37.00 | 0.43% |
| CAC 40 | 7,733.50 | 23.75 | 0.31% |
| DAX 40 | 20,990.31 | 86.92 | 0.42% |
| Dow JONES (US) | 43,487.83 | 334.70 | 0.78% |
| FTSE 100 | 8,520.54 | 15.32 | 0.18% |
| HKSE | 19,925.81 | 341.75 | 1.75% |
| NASDAQ | 19,630.20 | 291.91 | 1.51% |
| Nikkei 225 | 38,902.50 | 451.04 | 1.17% |
| NZX 50 Index | 13,088.31 | 42.12 | -0.32% |
| S&P 500 | 5,996.66 | 59.32 | 1.00% |
| S&P/ASX 200 | 8,347.40 | 37.00 | 0.45% |
| SSE Composite Index | 3,244.38 | 2.56 | 0.08% |